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Abstract The Iberian lynx is the most endangered felid
species. During winter/spring 2006/7, a feline leukemia
virus (FeLV) outbreak of unexpected virulence killed about
2/3 of the infected Iberian lynxes. All FeLV-positive ani-
mals were co-infected with feline hemoplasmas. To further
characterize the Iberian lynx FeLV strain and evaluate its
potential virulence, the FeLV envelope gene variable
region A (VRA) mutant spectrum was analyzed using the
Roche 454 sequencing technology, and an in vivo trans-
mission study of lynx blood to specified-pathogen-free cats
was performed. VRA mutations indicated weak apolipo-
protein B mRNA editing enzyme and catalytic polypep-
tide-like cytidine deaminase (APOBEC) restriction of
FeLV replication, and variants characteristic of aggressive
FeLV strains, such as FeLV-C or FeLV-A/61C, were not
detected. Cats exposed to FeLV/Candidatus Mycoplasma
haemominutum-positive lynx blood did not show a
particularly severe outcome of infection. The results
underscore the special susceptibility of Iberian lynxes to
infectious diseases.
Introduction
The Iberian lynx (Lynx pardinus) is the most endangered
felid in the world [34]. Not more than 200-250 animals
remain, confined to two isolated populations in southern
Spain: Don˜ana and Sierra Morena [20]. The genetic
diversity in the Iberian lynx is very low, especially in the
Don˜ana population [37] and may contribute to render the
species particularly susceptible to pathogens [57]. In win-
ter/spring 2006/7, an outbreak of feline leukemia virus
(FeLV, a gammaretrovirus occurring naturally in domestic
cats and some small felids worldwide [33, 43]) killed 7 out
of 11 viremic animals [56].
Four subtypes of FeLV are known [2]: while FeLV-A is
present in all FeLV-infected cats, FeLV-B arises by
recombination between FeLV-A and an endogenous FeLV-
related sequence, and FeLV-C and FeLV-T evolve through
mutation of FeLV-A. The latter two cause pure red cell
aplasia and a fatal immunodeficiency syndrome, respec-
tively. The virus found in the Iberian lynxes is closely
related to FeLV-A: the envelope gene from the first lynx
found positive at the beginning of the epidemic shows
98.1% and 97.0% identity to FeLV-A/61E (GenBank
accession M18247) and FeLV-A/Rickard (GenBank
accession AF052723) reference strains, respectively, and
99.7-100% identity to FeLV blood and tissue viral DNA
consensus sequences of the affected Iberian lynxes eight
months later [9, 56]. The consensus sequences did not show
the presence of highly pathogenic FeLV-A or FeLV-C
variants [56], and FeLV-B cannot exist in Iberian lynxes
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because of the absence of endogenous FeLV-related
sequences in their genome [56].
Four different outcomes of FeLV infection are known
in domestic cats: abortive (no virus detected in blood after
exposure, with or without bone marrow infection [54]),
regressive, progressive, and the rare focal or atypical
infection (no viremia, virus replication only in defined
tissues) [31]. The majority of domestic cats exposed to
FeLV develop regressive infection (with or without tran-
sient viremia) characterized by the presence of integrated
viral DNA in the blood [8], low viral RNA and DNA
loads, reduction or absence of antigenemia [31], and
production of neutralizing antibodies [21], but the virus
can occasionally be reactivated, e.g., through immunosu-
pression [73]. Progressively infected cats shed the virus
continuously and can live for several years without
developing disease symptoms, usually succumbing to
subsequent FeLV-associated diseases [17]. The course of
infection is influenced by both host and viral factors, and
co-infections [42, 63, 66], e.g., resistance to persistent
viremia, increase with the age of the host [32]. The
severity of the disease in the Iberian lynx was rather
unexpected, since in privately owned, persistently viremic
FeLV-infected domestic cats, a six-month survival rate of
about 90% and a mean survival time in the field of about
one year has been reported [24]. In addition, the rare
FeLV infections in Iberian lynx detected before 2006 did
not lead to severe disease [48, 56, 71]. Studies in several
populations of wildcats from Europe and the Middle East
have shown a relatively high prevalence of FeLV antige-
nemia [22, 43, 57, 62], and at least one other FeLV out-
break has been described in the Florida puma [14].
However, the latter did not have as dramatic of conse-
quences as the one seen in the Iberian lynx in 2007.
Another hallmark of the FeLV outbreak was the clear
association with infection by Mycoplasma haemofelis
(Mhf) and ‘Candidatus Mycoplasma turicensis’ (CMt) and
the absence of FeLV-positive lynxes free of hemoplasma
infection. No association with FeLV infection in the Ibe-
rian lynx was found for the other known feline hemopl-
asma, ‘Candidatus Mycoplasma haemominutum’(CMhm)
[56]. In recent studies in domestic cats, no association
between FeLV and hemoplasma infection was observed
[41, 53, 75, 83, 87], but FeLV and hemoplasma infection
are associated in European wildcats (Felis sylvestris) [88].
Thus, the association of FeLV and hemoplasma in the
Iberian lynx may be linked either to host genetics (i.e., a
general immune system dysfunction, which may support
the assumption that a retrovirus-positive status alone is
insufficient to induce hemoplasma disease and that retro-
virus-induced immunosuppression may be required for the
manifestation of hemoplasma-induced anemia [87]) or to a
peculiar characteristic of the infecting virus strain that
may have rendered the host more susceptible to specific
pathogens.
Several management actions were implemented to avoid
the spread of FeLV: progressively infected lynxes were
removed from the field, non-infected animals were vacci-
nated against FeLV, and grown wild and domestic cats
were removed in order to reduce inter-specific contacts
with lynxes [13, 46]. So far, these measures have been
successful: since 2007, the only new case had been from a
mother-to-cub transmission in late 2009 (Guillermo Lo´pez,
personal communication). Nevertheless, the potential
pathogenicity of the FeLV strain carried by the Iberian lynx
cannot be neglected—not only because of the damage
caused to the lynx population but also because retrans-
mission from lynxes to domestic cats of a particularly
virulent FeLV strain may have profound consequences, as
seen for cross-species transmission in other species [13, 28,
39, 61, 65, 84, 89]. Thus, the aim of this study was to assess
the disease-inducing potential of the lynx‘s FeLV. First,
one of the regions of the envelope gene variable region A
(VRA) of FeLV that is characteristic of extremely patho-
genic FeLV variants, i.e., FeLV-C [7, 76] or FeLV-A/61C
[63], was analyzed by next-generation sequencing. Second,
specific-pathogen-free (SPF) cats were inoculated with
either blood from a FeLV-viremic/CMhm- infected lynx,
with CMhm-infected blood from a FeLV-free lynx mixed
with the FeLV-A/Glasgow-1 strain or with the FeLV-A/
Glasgow-1 strain alone, and the course of infection was
followed for 20 weeks post-infection (p.i.).
Materials and methods
Ultra-deep sequencing of circulating viruses
and proviruses from the Iberian lynxes
Plasma viral RNA and blood viral DNA from three Iberian
lynxes were analyzed. The samples originated from the first
lynx that had been tested positive for FeLV in December
2006 (lynx ‘‘Roman’’) and probably started the epidemic;
from a lynx (‘‘Uda’’) that also died in 2007; and from a
lynx (‘‘Coca’’) sampled in 2009 that was infected in 2007,
yet survived up to now despite progressive FeLV infection.
Blood samples from the lynx ‘‘Coca’’ were subsequently
used for the transmission study. Reverse transcription of
viral RNA was performed on 5 ll of plasma-extracted total
nucleic acid (TNA) using an ABI high-capacity cDNA kit
(Applied Biosystems, Rotkreuz, Switzerland) at a final
concentration of 600 nM each of primers 8197R and 8262R
(Table 1) in a final volume of 25 ll according to the
manufacturer’s instructions with incubation times of 25C
for 10 min, 37C for 60 min and 70C for 10 min. Samples
were stored on ice until further processing. PCR generation
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of an 800-bp amplicon was performed on a Biometra
gradient cycler (Biometra GmBH, Goettingen, Germany)
using 2 ll amplified cDNA (for virus sequencing) or of
blood TNA (for provirus sequencing), and forward and
reverse primers tagged for multiplexing (Table 1) at a final
concentration of 500 nM each with 0.4 ll 10 mM dNTP,
4 ll 5x GC buffer, and 0.5 ll Phusion Hot Start Taq
Polymerase (2 U/ll, Finnzymes, Keilaranta, Finnlad) in a
Table 1 Primers used. Italic bold underlined: tag-key, which allows differentiation of the samples after sequencing; the sequence on the key 5’
side is 454-sequencer-specific, the sequence on the key 3’ side is FeLV-specific. n.a. = not applicable
Name 5’-3’ sequence Length Product
length (bp)
Target/reference
FeLV subtyping primers
FeA-F
RB59
CAATGTAAAACACGGGGCAC 20 1071 FeLV-A subtype [16,
55]
FeA-R
RB17
TAGTGATATTGGTTCTCTTCG 21
FeB-F
RB53
ACAACGGGAGCTAGTG 16 857 FeLV-B subtype [55,
77]
FeB-R
RB17
TAGTGATATTGGTTCTCTTCG 21
FeC-F
RB58
AGATCTTGGGCACGTTATTCC 21 1754 FeLV-C subtype [77]
FeC-R
RB47
TTGTGAAATGGCATTGCTGC 20
Primers for reverse transcription
8197R GAAGGTCGAACCCTGGTCAACT 22 n.a. FeLV LTR [56]
8262R TTATAGCAGAAAGCGCGCG 19
Next-generation multiple sequencing primers
NGSA-
CTA-F
GCCTCCCTCGCGCCATCAGctaCATGTWGACTTATGTGACCTAGTGGG 48 794 Reference (GenBank
EU293182)
NGSB-
CTA-R
GCCTTGCCAGCCCGCTCAGctaGGTCGAGAAACCAGGCAGA 41
NGSA-
ATC-F
GCCTCCCTCGCGCCATCAGatcCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Roman’’ blood virus
NGSB-
ATC-R
GCCTTGCCAGCCCGCTCAGatcGGTCGAGAAACCAGGCAGA 41
NGSA-
ATA-F
GCCTCCCTCGCGCCATCAGataCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Roman’’ blood
provirus
NGSB-
ATA-R
GCCTTGCCAGCCCGCTCAGataGGTCGAGAAACCAGGCAGA 41
NGSA-
ACA-F
GCCTCCCTCGCGCCATCAGacaCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Uda’’ blood virus
NGSB-
ACA-R
GCCTTGCCAGCCCGCTCAGacaGGTCGAGAAACCAGGCAGA 41
NGSA-
AGA-F
GCCTCCCTCGCGCCATCAGagaCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Uda’’ blood provirus
NGSB-
AGA-R
GCCTTGCCAGCCCGCTCAGagaGGTCGAGAAACCAGGCAGA 41
NGSA-
TCA-F
GCCTCCCTCGCGCCATCAGtcaCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Coca’’ blood virus
NGSB-
TCA-R
GCCTTGCCAGCCCGCTCAGtcaGGTCGAGAAACCAGGCAGA 41
NGSA-
TGA-F
GCCTCCCTCGCGCCATCAGtgaCATGTWGACTTATGTGACCTAGTGGG 48 794 ‘‘Coca’’ blood provirus
NGSB-
TGA-R
GCCTTGCCAGCCCGCTCAGtgaGGTCGAGAAACCAGGCAGA 41
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final volume of 20 ll. Cycling conditions were as follows:
an initial denaturation of 30 sec at 98C followed by 40
cycles of 98C for 10 sec, 64C for 30 sec and 72C for
20 sec with a final extension step of 72C for 2 min.
Successful amplification was verified by gel electrophore-
sis on a 2% TAE agarose gel, and the specific band was
excised and purified using a GenElute PCR Clean-Up Kit
(Sigma-Aldrich). The product was eluted with 30 ll water,
and 5 ll thereof was visualized again by gel electropho-
resis. The concentration of the purified PCR products was
measured using a Quant-iTPicoGreen dsDNA Reagent
Kit (Invitrogen) on a Rotorgene 6000 (Corbett Life Sci-
ences, Brisbane, Australia) according to the manufacturer’s
instructions. For next-generation sequencing, 100 ng of
DNA was prepared after normalizing the samples to 10
ng/ll and pooling them together. Multiplex sequencing was
performed at the Functional Genomics Center Zurich
(Zurich, Switzerland) on a Roche 454 Genome Sequencer
(Roche, Basel, Switzerland) using a GS FLX Standard
Amplicon Kit (Roche) according to the manufacturer’s
instructions. The amplicons were sequenced starting from
the forward primers. The resulting sequences were quality-
and length-filtered (minimum read quality [20 for each
read, length within the 95% confidence interval around the
mean [26], i.e., 261-283 bases) and sorted according to
their tags using the Galaxy pipeline at Penn State Univer-
sity, USA (http://galaxy.psu.edu/). The workflow used
is available online (http://main.g2.bx.psu.edu/u/vcattori/w/
fastq-filter-on-iberian-lynxes-454-dataset). Variant geno-
type analysis was performed using the SNP caller built in
Geneious Software (version 5.0, Biomatters Ltd, Auckland,
New Zealand). Variants were called if their frequency
exceeded the expected 95% confidence interval for the
binomial distribution of the variants detected while
sequencing a reference plasmid that carried the same
sequence as that of FeLV from the Iberian lynx (GenBank
accession EU293182). Sequencing reads are deposited in
the NCBI sequence read database (Accession number
SRA020778.1) and can also be retrieved in Sanger FASTQ
from http://main.g2.bx.psu.edu/u/vcattori/h/public.
Viral titers
Tissue culture infectious doses 50 (TCID50) were calcu-
lated using five-fold serial dilutions of the viruses. For each
virus dilution tested, six wells of a 24-well plate, each with
10,000 QN10 cells, were incubated for 2 hours at 37C
with 250 ll virus diluted in cell culture medium [36]. The
inoculum was washed away and the cells cultured further
in 400 ll medium for 8 days with addition of 400 ll
medium after 4 days. The presence of infectious virus was
determined by p27 ELISA as described [49], and TCID50
was calculated using the Karber formula [38].
In vivo transmission study: SPF cats
Sixteen 8-week-old SPF male domestic kittens (Liberty
Research Inc., Waverly, NY, USA) were included in this
study. The cats were divided into four groups of four cats
each and housed in separate rooms under barrier condi-
tions. All SPF cats were examined clinically prior to the
study, and their SPF status was verified as described pre-
viously [60]. Identical methods were used to screen the
lynxes designated as blood donors for the in vivo trans-
mission study. EDTA serum was negative for FeLV p27
antigen and for antibodies against FCoV, FCV, FHV1,
FPV, and FIV [29, 51, 70]. The cats and the potential donor
lynxes were blood typed using a commercial gel column
technique (ID-Gel Test Feline A?B Typing; DiaMed AG,
Cressier sur Morat, Switzerland).
Experimental design and infection
Cats of group ‘‘Iberian lynx - CMhm’’ (IbL-CMhm, cats
LM1-LM4) received blood from a FeLV- and CMhm-posi-
tive Iberian lynx, a two-year old male called ‘‘Coca’’, which
survived the outbreak in 2007 and belonged to the free-
ranging Coto del Rey subpopulation in the Don˜ana area
before being removed from the field. Each cat of group IbL-
CMhm received 1 ml of EDTA blood in 20% dimethyl
sulfoxide (DMSO, Sigma-Aldrich, Buchs, Switzerland). The
blood was stored at room temperature during shipment from
Spain to Switzerland (24 h), preserved in 20% DMSO after
receipt and stored in liquid nitrogen until use. The blood was
positive for FeLV (p27 60% of the laboratory control, 9.8 x
107 copies virus/ml, a titer of approximately 2,000 focus-
forming units (FFU)/ml as estimated by TCID50 comparison
with the Glasgow-1 stock virus used for the other groups) and
for CMhm (6.9 x 105 copies/ml). Cats of the group ‘‘FeLV-A/
Glasgow-1-CMhm’’ (G1-CMhm, cats GM1-GM4) were
inoculated with blood from an FeLV-negative, CMhm-
positive lynx together with a prototype FeLV-A virus strain
(FeLV-A/Glasgow-1 [35]). Each cat received 1 ml of EDTA
blood in 20% DMSO. The blood was collected from a free-
ranging female Iberian lynx called ‘‘Esperanza’’ captured as
cub from the Don˜ana area and held in captivity since, shipped
at the same time as the group IbL-CMhm blood and handled
identically. Esperanza’s blood was positive by PCR for
CMhm only (3.7 x 105 copies/ml). In addition, the cats
received 0.2 ml FeLV-A/Glasgow-1 strain (500,000 FFU,
1.35 x 1010 viral RNA copies/ml inoculum) [35]. The two
inocula were injected intraperitoneally with separate syrin-
ges. Cats of group ‘‘Felv-A/Glasgow1’’ (G1, cats G1-G4)
served as an FeLV-A/Glasgow-1-only control group. They
received 0.2 ml FeLV-A/Glasgow-1 strain (500,000 FFU) in
20% DMSO and 0.6 ml RPMI medium (Invitrogen AG,
Basel, Switzerland), and cats C1-C4 (control group) served
842 C. P. Geret et al.
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as uninfected age-matched negative controls. They were
inoculated with 1 ml RPMI medium (Invitrogen AG) in 20%
DMSO. All cats were inoculated intraperitoneally at the age
of 12 weeks. All inocula were thawed at 37C and stored on
ice until use. The cats were monitored daily for signs of
illness after virus inoculation; body temperature and weight
were recorded at each sampling day. To monitor for cryptic
infections transmitted via lynx blood to the SPF cats, path-
ogen screening was performed again at week 16 p.i. as
described above.
Sample collection and processing
Blood samples were collected under light anesthesia
(3 mg/kg S-Ketamin (Keta-S; Dr. E. Graeub AG, Bern,
Switzerland), 5 lg/kg Medetomidin (Dorbene; Dr.
E. Graeub AG), and 0.2 mg/kg Butorphanol (Morphasol-
4; Dr. E. Graeub AG), administrated intramuscularly) at
the time point of infection (week 0) and at weeks 1 to 6, 8,
10, 13, 16, and 20 p.i. Plasma was recovered from EDTA-
anticoagulated blood after centrifugation for 10 min at
1700 g. Plasma and whole blood samples were immedi-
ately frozen at -80C until use, with the exception of the
hematology samples, which were processed at once. He-
mograms were performed using a Sysmex XT-2000iV
(Sysmex Corporation, Kobe, Japan) [85]. Packed cell vol-
ume (PCV) values between 22% and 39% and leucocytes
between 4,600/ll and 12,800/ll (5% and 95% quantiles)
were considered to be within the reference range. Bio-
chemical test were performed on an automated analyzer
(Cobas Integra 800, Roche Diagnostics, Rotkreuz, Swit-
zerland). The infected cats were euthanized at week 20 p.i.
Detection and quantification of FeLV blood viral DNA
and plasma viral RNA and CMhm loads by real-time
PCR and RT-PCR
TNA was extracted from a volume of EDTA-anticoagulated
blood containing 106 leucocytes or from a maximum volume
of 100 ll using a MagNA Pure LC Total Nucleid Acid
Isolation Kit (Roche diagnostics AG, Rotkreuz, Switzer-
land). Cell copy numbers, FeLV proviral DNA quantities
and CMhm loads were determined by real-time PCR as
described [79, 86, 87]. For detection of FeLV viral RNA in
plasma, TNA was extracted from 200 ll EDTA plasma
using a MagNA Pure LC Total Nucleic Isolation Kit (Roche)
and quantified by real-time RT-PCR as described [79].
Detection of FeLV p27 antigen and FeLV antibodies
by ELISA and western blot
FeLV viremia was determined by p27 double antibody
sandwich ELISA as described [50]. Results were calculated
as the percentage of a positive control (culture supernatant
of FL-74 feline lymphoblastoid cell line permanently
infected with FeLV), which was assayed with every plate.
Values above 4% were considered to be positive. In
agreement with the European Pharmacopoeia (2005), a cat
was designated progressively infected when FeLV p27
antigen was positive for three consecutive weeks or on five
occasions between weeks 3 and 15 p.i. Anti-FeLV whole
virus antibodies were determined by ELISA using 100 ng
of gradient-purified FL-74 FeLV and a plasma dilution of
1:100 as described [49]. Values above 25% of a SPF-serum
pool were considered to be positive. In addition, FeLV
antibodies were detected by western blot at weeks 0 and
20 p.i. as described [52], using serum obtained from a pool
of immune cats and a mixture of monoclonal antibodies
against p27, p15E and gp70 as a positive control [54].
FeLV subtyping
TNA (2 ll) extracted from blood collected from all cats
at week 20 p.i. (with the exception of GM1 and LM1,
which were sacrificed for humane reasons at weeks 10
and 13 p.i., respectively) and from the FeLV viremic lynx
used for the transmission experiment, was analyzed by
conventional PCR for the presence of FeLV-A, -B and -C
subtypes using previously described primers (Table 1)
[16, 55, 56, 77]. Each reaction contained a final concen-
tration of 500 nM of each primer with 0.4 ll 10 mM
dNTP, 4 ll 5x Phusion HF Buffer, and 0.2 ll Phusion
Taq Polymerase (2 U/ll, Finnzymes, Keilaranta, Finnlad)
in a final volume of 20 ll. Target sequences were
amplified on a Biometra gradient cycler (Labrepco, Hor-
sham PA, USA) under the following conditions: initial
denaturation for 2 min at 98C followed by 40 cycles of
98C for 20 sec, 52C (FeLV-C) or 64C (FeLV-A/-B)
for 30 sec and 72C for 80 sec with a final elongation
step of 72C for 10 min. PCR products were visualized
by agarose gel electrophoresis.
Statistics
Due to the limited number of animals per group, we
abstained from using a parametric approach and used a
robust test instead. Longitudinal effects on FeLV viral,
FeLV proviral, and antibody loads of the different groups
were compared to each other using the area under the curve
(AUC) and Mann-Whitney tests. Longitudinal effects on
CMhm on the time until the bacterial peak were deter-
mined using the Mann-Whitney test. Outcomes between
groups were compared using Fisher’s exact test. P-values
\0.05 were considered statistically significant. Analyses
were conducted using the R-package (version 10.0, The R
Foundation for Statistical Computing, Vienna, Austria) and
Feline leukemia virus outbreak in Iberian lynx 843
123
GraphPad software (version 5.00, GraphPad Software Inc.
La Jolla, CA, USA).
Results
Characterization of circulating viruses
The FeLV viral RNA and proviral DNA envelope gene
VRA from the three lynxes ‘‘Roman’’, ‘‘Uda’’ and ‘‘Coca’’
were analyzed (Fig. 1). A total of 3299 reads from a
plasmid reference were analyzed for 454 sequencing error
correction. The error rate was of 2.55% with a transition/
transversion rate of 1.94, and the majority of errors were
G-to-A and C-to-T transitions (16.8 and 14.4%, respec-
tively, of the sequencing errors). After error correction, the
sequences from the Iberian lynxes were 87.3 to 97.1%
identical to the reference sequence over 238 bases (posi-
tions 150-387 of GenBank EU293182, Table 2). Mapping
of the variants was possible for mutations that occurred in
[0.2% of the viral/proviral sequences. No deletions or
variants characteristic of the highly pathogenic FeLV-C [7,
76] or FeLV-A/61C [63] were found in the VRA (Fig. 1).
Of the 25 sites of variation identified, 15 were due to a
G-to-A substitution. Ten of the 25 sites found were con-
served in the 2007 and 2009 sequences (Fig. 1 and
Table 2). Twelve of the 15 G-to-A substitutions caused a
nonsynonymous amino acid substitution, while only three
nonsynonymous substitutions occurred in the other 10
variant sites. Nonsynonymous substitutions were mainly
tryptophan to stop codon and glycine to arginine (Fig. 1
and Table 2). Overall, around 85% of the G-to-A substi-
tutions identified caused a nonsynonymous substitution
(Table 3). Substitutions other than G to A only caused
nonsynonymous substitutions in a maximum of 40% of the
sequences (Table 3). Furthermore, The fifteen G-[A sites
of the lynx FeLV variant spectrum are embedded in 8
different trinucleotide contexts (Table 2), three G-[A sites
(positions 10, 161 and 176) are present in all six samples
analyzed, and three (74, 157, 173) in five out of six samples
(Fig. 1 and Table 2).
Characteristics of Iberian lynx blood used as inoculum
The lynx blood that was used for the transmission experi-
ment was PCR/RT-PCR negative for all tested feline
Fig. 1 FeLV sequence variants in the Iberian lynxes. Variations
appearing at a frequency [0.2% and comparison with variations
occurring in highly pathogenic FeLV strains are depicted. Differences
from the Iberian lynx reference sequence are highlighted, with each
nucleotide (A) and amino acid (B) shown with a different color. FeLV
envelope VRA is indicated by a horizontal bar. A) DNA sequence
comparison. FeLV-A/EH1161 and FeLV-A/61C are involved in
feline AIDS pathogenesis [63]; FeLV-FY981 represents the transition
between FeLV-A and FeLV-C subtypes [7, 76]. The samples
‘‘Roman’’, ‘‘Coca’’ and ‘‘Uda’’ originated from the first lynx that
tested positive for FeLV in December 2006 (‘‘Roman’’) and probably
started the epidemic; from a lynx (‘‘Uda’’) that also died in 2007; and
from a lynx (‘‘Coca’’) sampled in 2009 that was infected in 2007, yet
survived up to now despite progressive FeLV infection. The GenBank
accession numbers of the sequences are as follows: EU293182 (lynx
reference), M87886 (EH1161), M18246 (61C), FJ436991 (FY981),
M14331 and M89998 (FeLV-C). B) Nonsynonymous substitutions
deriving from mutations in the DNA sequences from A)
844 C. P. Geret et al.
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Table 2 Variant frequency in the Iberian lynx FeLV after filtering of
Roche 454 genome sequencer data. CID (%): percentage of
sequencing reads identical to the reference sequence. Nucleotide:
nucleotide substitution from -[ to base. For G-[A substitutions, the
trinucleotide is given, with the central G being substituted. Position:
position of the substitution in the reference sequence (see Fig. 1).
Freq (%): frequency (%) of sequences showing the point variation at
the position given. Substitution: amino acid substitution due to the
mutation, -: synonymous substitution
Sample 454 reads CID (%) Nucleotide Position Freq (%) Substitution
Roman RNA 5969 92.3 GGG 10 0.6 W-Stop
GGC 50 0.2 A-[T
TGG 74 1.0 G-[R
CGA 157 1.7 –
GGG 161 1.4 G-[R
TGG 173 1.2 G-[R
AGG 176 0.9 G-[R
CGG 221 0.2 G-[R
TGG 234 0.5 W-[Stop
Roman DNA 759 87.3 GGG 10 0.7 W-[Stop
T-[C 16 0.3 –
A-[G 35 0.3 N-[D
GGC 50 0.4 A-[T
C-[T 53 0.3 R-[C
C-[A 60 0.3 S-[Y
TGG 74 1.4 G-[R
TGT 78 0.3 C-[Y
C-[A 118 0.3 –
C-[T 130 0.7 –
CGA 157 1.9 –
GGG 161 2.1 G-[R
TGG 173 1.4 G-[R
AGG 176 0.7 G-[R
GGC 179 0.9 A-[T
CGC 200 0.4 A-[T
CGG 221 0.3 G-[R
TGG 234 0.3 W-[Stop
Uda RNA 4222 97.5 GGG 10 0.2 W-[Stop
A-[G 52 0.2 –
CGA 157 0.3 –
GGG 161 0.6 G-[R
TGG 173 0.6 G-[R
AGG 176 0.6 G-[R
Uda DNA 684 95.9 GGG 10 0.3 W-[Stop
A-[G 52 0.4 –
TGG 74 0.3 G-[R
CGC 148 0.4 –
GGG 161 1.0 G-[R
AGG 176 1.0 G-[R
GGC 179 0.6 A-[T
Coca RNA 6165 96.1 GGG 10 0.5 W-[Stop
G-[A 74 0.2 G-[R
C-[T 124 0.2 –
CGA 157 0.5 –
GGG 161 1.1 G-[R
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pathogens with the exception of FeLV and CMhm, as
described above. Inadvertently, the sample from the lynx
used for group IbL-CMhm was serologically positive for
antibodies to the feline calicivirus (immunofluorescence
titer of 1:320). No antibodies against the other tested
unwanted pathogens were detected. Both lynxes were of
blood type A, as were all of the SPF cats in the present study.
Outcome of the FeLV transmission study
All cats of groups IbL-CMhm, G1-CMhm and G1 became
infected with FeLV. Cats of the control group stayed FeLV-
negative. According to the results obtained from p27 ELISA,
the four cats of groups G1-CMhm and G1 and two cats of
group IbL-CMhm (LM2, LM1) developed a progressive
FeLV infection. The other two cats of group IbL-CMhm
(LM3-LM4) were regressively infected (Fig. 2A). All cats of
groups IbL-CMhm, G1-CMhm and G1 became FeLV pro-
virus and viral RNA positive (Fig. 2B and C). There was no
statistical difference in the outcomes (regressive vs pro-
gressive) among the three different groups, and this was
independent of the FeLV strain used (lynx vs FeLV-A/
Glasgow-1) and the absence or presence of CMhm co-
inoculation. Differences were found between viral RNA
loads of group G1 vs IbL-CMhm (p=0.0286) and G1-CMhm
vs IbL-Cmhm (p=0.0286), and proviral loads of group G1 vs
IbL-CMhm (p=0.0286). There was no statistical difference
in the p27 values among the three groups. FeLV subtyping
revealed that FeLV-B was present in one cat (R1) of group
G1 at euthanasia 5 months p.i. The other cats of groups IbL-
CMhm, G1-CMhm and G1 were positive for the FeLV-A
subtype only. All cats were negative for FeLV-C.
Seroconversion to FeLV was found in all exposed cats,
but not in cats of the control group. The FeLV-infected cats
turned positive starting at weeks 1 to 2 p.i. Three cats of
group IbL-CMhm (LM-2-LM4) showed a high humoral
immune response against FeLV until the end of the
experiment, while only two out of the remaining seven
progressively infected cats (G3-G4, group G1) were still
positive for FeLV whole-virus antibodies at the end of the
experiment (Fig. 2D). Antibody levels to FeLV varied
significantly over time until week 13 p.i. between the
groups G1 and IbL-CMhm (p=0.0286), with group IbL-
CMhm having the highest levels. This was also reflected by
western blot results (Fig. 3): serum samples from 4 out of
12 FeLV-infected cats were western blot positive at week
20 p.i. (Fig. 3), and this included three cats of the group
IbL-CMhm (LM2, LM3, LM4) and one cat of the group
G1-CMhm (GM1). The two regressively infected cats,
LM3 and LM4, were positive for p58, p27 and p15E, cat P2
was weakly positive for p58 and strongly positive for p15E,
and cat GM1 was weakly positive for p15E.
Outcome of CMhm infection
All cats were hemoplasma PCR negative prior to inoculation.
Seven of eight CMhm-inoculated cats became CMhm PCR-
positive in the blood: three cats of group IbL-CMhm and all
four cats of group G1-CMhm. One cat (LM1) of group IbL-
CMhm was never positive during the whole experiment.
While all four cats of group G1-CMhm and one cat of group
IbL-CMhm became positive by week 1 p.i., the remaining
two cats of the group IbL-CMhm turned positive at week 3
and 6 p.i., respectively (Fig. 4). No significant difference in
Table 2 continued
Sample 454 reads CID (%) Nucleotide Position Freq (%) Substitution
TGG 173 1.0 G-[R
AGG 176 0.5 G-[R
Coca DNA 6382 92.1 C-[A 7 0.3 –
GGG 10 0.2 W-[Stop
A-[G 43 0.3 –
TGG 74 1.0 G-[R
TGT 78 0.4 C-[Y
CGC 148 0.4 –
CGA 157 0.4 –
AGG 160 0.6 –
GGG 161 1.5 G-[R
TGG 173 0.5 G-[R
AGG 176 1.2 G-[R
TGG 188 0.2 G-[R
CGG 221 0.4 G-[R
TGG 234 0.4 W-[Stop
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copy numbers was found between groups after week 6 p.i.
Nevertheless, the overall course of CMhm infection was
significantly different between the two groups (time-to-peak
p = 0.0498), where group IbL-CMhm showed the slowest
progression. Clinical signs of CMhm infection were absent
in the recipient cats. Anemia was observed in one cat (LM1,
group IbL-CMhm) in which the PCV dropped from 25% to
18% before euthanasia at week 13 p.i., well below the ref-
erence range for the age of the cat [1]. However, this cat was
never positive for CMhm in blood.
Hematology results and clinical impact
of the transmission
PCV values showed age-related fluctuation during the
observation time but remained within the reference range.
There was no significant difference in PCV and white
blood cell counts between groups. Two cats had to be
euthanized during the experiment. Cat GM1 (group
G1-CMhm) developed a fatal panleukopenia at week
10 p.i., and cat LM1 (group IbL-CMhm) developed skin
lesions on the back, head and neck at weeks 8 to 10 p.i.
and, later on, an edema on the abdomen. At week 13 p.i.,
cat LM1 had to be euthanized for humane reasons. The
PCV was 18%, with a low total protein of 32.8 g/l (refer-
ence: 64-80), albumin of 11.6 g/l (reference 30-40),
increased lipase 558 U/L (reference 8-26) and amylase of
2,241 U/L (reference: 700-1,538), and 2,300 leukocytes/ll
(reference range 4,600-12,800). Upon necropsy, in addition
to the distinct edema, middle-grade acute pancreatitis and
omentitis were found.
Post-infection pathogen screening
At week 16 p.i., a second pathogen screening was per-
formed to test for cryptic infections transmitted via lynx
blood. Indeed, cat LM2 (group IbL-CMhm) was found to
be seropositive for FCV (titer 1:160) and FHV1 (titer of
1:320). Conjunctiva and saliva swabs extracted and tested
by RT-/PCR were negative at this time point. Retrospective
testing of all earlier time points revealed that this cat was
weakly positive for FHV1 by real-time PCR analysis of
blood at week 1 p.i. (crossing threshold of 36.9), when it
was weakly seropositive (titer of 1:20) as well. This cat was
seropositive for FHV1 at weeks 10 and 13 p.i. (titer of 1:40
and 1:160), and was first positive for FCV at week 13 p.i.
(titer of 1:80).
Discussion
The aim of this study was to further characterize the FeLV
strain prevailing during a severe disease outbreak in Iberian
lynxes in 2007 and to assess its pathogenic potential in
domestic cats. For animal-welfare reasons, we had to
minimize the number of animals used. Little is known
about how hemotropic mycoplasma and FeLV interact, and
dissecting the interactions between FeLV, hemotropic
mycoplasma (which are clearly associated only in FeLV
infection of the Iberian lynx [56]) and Iberian lynx blood in
the domestic cat model would have required too large of a
number of animals. Thus, far from being comprehensive,
this analysis focused on three factors that, in our view, are
important for the analysis of the pathogenic potential of the
Iberian lynx FeLV. The first is the sequence analysis of
FeLV envelope VRA, which was conducted using Roche
454 technology on plasma viral RNA and blood TNA
samples. In addition, an in vivo transmission study was
performed in which blood from an infected Iberian lynx
Table 3 Type and number of variations and nonsynonymous sub-
stitution frequency. Rows: base in the reference. Columns: substitu-
tion in the variant. (): % of derived nonsysnonymous substitutions
A C G T
Roman RNA
A
C
G 460 (88)
T
Roman DNA
A 2 (100)
C 4 (50) 7 (29)
G 82 (83)
T 2 (0)
Uda RNA
A 8 (0)
C
G 97 (83)
T
Uda DNA
A 3 (0)
C
G 25 (88)
T
Coca RNA
A
C 12 (0)
G 234 (87)
T
Coca DNA
A 19 (0)
C 19 (0)
G 460 (81)
T
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that was infected in 2007 and held in captivity ever since
was transmitted to a group of SPF cats to assess extreme
effects of the infection. Thirdly, the interaction between
mycoplasma/Iberian lynx blood and FeLV was addressed
in the well-tested FeLV-A/Glasgow-1 model using stan-
dard infectious viral doses.
Because the VRA of the FeLV envelope is one of the
regions of the viral genome that contributes to the
mutations characteristic of highly pathogenic FeLV
strains (Fig. 1), the viral RNA and DNA sequence vari-
ation of this region was compared in lynxes that died in
2007, at the beginning of the FeLV epidemic, and in the
Fig. 2 FeLV antigen p27 (A), proviral (B), plasma viral RNA
(C) and FeLV whole-virus (FL-74) antibodies (D) during the course
of the experimental transmission study. The threshold for p27-
positive results (A) is 4% of the positive control. Group IbL-CMhm:
cats LM1-LM4. Group G1-CMhm: cats GM1-GM4. Group G1: cats
G1-G4. Control group: cats C1-C4. Cats GM1 and LM1 were
euthanized at weeks 10 and 13 p.i., respectively. The red line in
D represents the threshold for positive results (25% of the positive
control)
Fig. 3 FeLV western blot analysis of plasma samples collected at
week 0 (prior to challenge) and week 20 p.i. from the 16
experimentally infected SPF cats (with the exception of cats GM1
and LM1, from which the last samples were collected at weeks 10 and
13 p.i., respectively. The positions of FeLV p15E (two bands), p27,
p58 and gp70 are highlighted (open arrows). Positive controls: serum
obtained and pooled from immune cats and a mixture of monoclonal
antibodies against FeLV gp70, p27, and p15E (Gp70, p27, p15E
mAB)
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blood to be used for the transmission experiment. The
remarkably high degree of identity found in both the
consensus sequence and in the variants of one of the most
changeable regions suggests that the overall characteris-
tics of the virus may have remained the same over time,
and the virus from 2009 was considered to be essentially
the same as the one that caused the FeLV outbreak in
2007. This is the virus source that mostly resembles the
original infecting strain, and its effect is more reliable
than molecularly cloned and amplified viruses. Deletions
or variations characteristic of highly pathogenic FeLV
strains were absent from the mutant spectrum of the
analyzed viral DNA and RNA sequence, suggesting that
the FeLV-A strain infecting the Iberian lynxes is not, per
se, extremely pathogenic, and other factors may have
contributed to enhancing its effect on Iberian lynxes.
However, since the determinants of pathogenicity of
viruses such as FeLV-C or FeLV-A/61C are not well
understood, variations in other regions may have con-
tributed to the virulence of the virus. For RNA sequenc-
ing, cDNA was prepared from TNA extracted from
plasma without DNase digestion. Therefore, a potential
viral DNA contamination could have occurred and influ-
enced our results. However, DNA contamination accounts
for a maximum of 0.5% of the total as assessed by one-
step real-time RT-PCR performed with or without reverse
transcriptase (our own observations). As the minimum
consensus identity is 83% (Table 2), this would lead to a
mutant DNA contamination of less than 0.1%, which is
not detectable under the analytical conditions used. In
addition, some mutations found in the RNA were not
detectable in the DNA sequences, and some mutations in
DNA sequences were not present in the RNA, although
their frequency would have resulted in detection if the
sample had been highly contaminated. Together, the
results do not suggest that DNA contamination influenced
the RNA sequencing results.
Of note, only the G-[A sites at position 78 (TGT-
[TAT) and 200 (CGC-[CAC) are not embedded in a
sequence context that may be compatible (although not
proof of) with the antiviral action of APOBEC cytidine
deaminases [12, 18, 44], and the six sites that are strongly
conserved among the analyzed samples (positions 10, 74,
157, 161, 173 and 176) are within a strong feline APOBEC
target sequence (AGG/GGG). Indeed, retrovirus restriction
by feline APOBECs has been characterized for vif-deleted
HIV and FIV [59, 78] and has been reported to be relatively
nonspecific (first position of the GG/GC or GA dinucleo-
tide [59]) or to show a preference for a purine before and/or
after the substituted guanine [78]. However, most of the
substitutions occurred alone within a single sequence,
indicating a weak restriction activity. APOBEC restriction
of FeLV replication was demonstrated in vitro for feline
APOBEC3CH [59], and extensive APOBEC editing,
although not associated with a clear effect on viral repli-
cation, has been shown in vitro and in vivo for Friend
murine leukemia virus, a gammaretrovirus related to FeLV
[67]. We therefore may expect more extensive editing of
FeLV in felids than was observed in Iberian lynxes. The
number of mutations caused by the action of APOBEC
proteins on FeLV infection in felids other than Iberian
lynxes is unknown, and therefore, no conclusion can be
drawn about the role of APOBEC editing (e.g., driving
virus evolution as proposed for HIV [40]) in FeLV infec-
tion in Iberian lynxes. Similar mutations have been
detected in some thymic tumor clones from a cat experi-
mentally infected with FeLV-A (GenBank accession
FLU03204, FLU03207, FLU03219, FLU03208) and could
potentially have been partly responsible for tumor devel-
opment [72]. However, a direct involvement of such
mutations (and therefore, indirectly, of APOBEC proteins)
in tumorigenesis has not been demonstrated so far and does
not seem to play a major role in the 2007 outbreak, since
tumors were apparently not the cause of death of the Ibe-
rian lynxes [56]. The structure of the long terminal repeats
(LTRs), which is known to influence the kinetics of FeLV
replication, could have contributed to the pathogenicity of
FeLV as well [4, 5, 11, 69]. However, LTR single genome
amplification from blood and the LTR consensus sequence
from kidney, liver and intestinal DNA from the lynx
‘‘Roman’’ did not reveal any tandem sequence duplication
that could have caused an increased pathogenicity of the
Iberian lynx FeLV, and the LTR sequences were 99%
identical to that of the reference strain FeLV-A/61E (data
not shown). Because all FeLV-infected Iberian lynxes were
co-infected with feline hemotropic mycoplasmas [56], no
transmission using blood containing only the lynx FeLV
could be attempted. To control for any effect that feline
hemoplasma (CMhm) from the lynx could have had on the
experimental transmission (group IbL-CMhm), a second
Fig. 4 Time course of CMhm loads in experimentally infected SPF
cats. Group G1-CMhm (cats GM1-GM4) and group IbL-CMhm (cats
LM1-LM4) loads are expressed as CMhm copies per ml blood. Cats
GM1 and LM1 were euthanized at weeks 10 and 13 p.i., respectively
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experimental group was introduced that received a proto-
type FeLV-A (FeLV-A/Glasgow-1) and the lynx CMhm
(group G1-CMhm). For this purpose, FeLV-free CMhm-
infected Iberian lynx blood was obtained as matched con-
trol CMhm. To further address possible influences of
CMhm coinfection on the pathogenesis of FeLV infection,
another control group of SPF cats was included and
infected with the FeLV-A/Glasgow-1 strain alone (group
G1). The high levels of viremia reached in the infected cats
(2-3 orders of magnitude higher than HIV, for example [6,
45]) were typical for a FeLV-A infection [10, 30, 79] in all
three groups. Due to the small group size, the outcome of
FeLV infection in these three groups was not significantly
different, although the IbL-CMhm group showed lower
levels of FeLV viral RNA and DNA loads during the
course of infection, and two of the cats from the same
group had a regressive infection. Even if no direct com-
parison of experimental infection using FeLV-A/Glasgow1
is available, cats infected intravenously with 200 FFU of
FeLV-A Rickard strain [68] at 8-10 weeks of age all
developed a progressive infection, and cats injected intra-
peritoneally with 50,000 FFU FeLV-A/Glasgow-1 showed
the same course of infection as cats injected with a 10x and
100x higher load [25]. Hence, the IbL-CMhm group
showed a similar, if not better, response to the infection as
the one that may be expected using the same amount of
FeLV-A/Glasgow-1 strain.
One cat of Group G1-CMhm (GM1) was diagnosed with
fatal panleukopenia at week 10 p.i., which can develop
during FeLV infection as a result of FeLV replication in the
bone marrow [33, 74]. We therefore assume that a potential
contribution to increased pathogenicity of FeLV from
intrinsic factors present in the Iberian lynx blood is not
likely.
In addition, whole-virus antibody levels varied signifi-
cantly between group G1 and IbL-CMhm, and western blot
analysis indicated that three cats of group IbL-CMhm may
have become regressively infected. This is in agreement
with the fact that a much lower titer of the lynx FeLV was
used for infection compared to the *250x higher FeLV-A
prototype FeLV-A/Glasgow-1 dose used to infect cats of
groups G1-CMhm and G1. The low dose may have con-
tributed to the establishment of a lower number of pro-
gressive infections.
Although the cause of disease in cat LM1 is still unclear,
biopsy of a skin lesion (neck) was positive for FeLV
nucleic acid and FeLV antigens, as demonstrated by
RT-PCR and immunohistology, respectively (data not
shown). This may explain the sudden lesions, as ulcerative
dermatitis is described for FeLV-infection [19]. Intestinal
protein loss may have been responsible for the very low
protein concentration and development of edema, a pattern
associated with FeLV-related diseases such as intestinal
lymphoma. Interestingly, although intestines, liver and
kidneys were examined macroscopically and microscopi-
cally for the presence of lymphoma, no evidence of neo-
plasia was found. Thus, the etiology of the extremely low
plasma protein concentration was not elucidated.
Cat P2 showed signs of contact with FHV1 and FCV,
implying that these two pathogens had been present in the
lynx blood in quantities below the detection limit of the
PCR assays. Nevertheless, these subclinical infections
introduced through lynx blood inoculation apparently did
not influence the outcome of FeLV infection, since this cat
may have progressed towards a regressive infection
according to our serological results.
We report here, to our knowledge, the first successful
feline hemoplasma transmission after 24 h storage of the
blood at room temperature followed by cryopreservation.
The course of CMhm infection in cats of group IbL-
CMhm was significantly different from that seen in group
G1-CMhm, despite of the similar CMhm loads in the
blood utilized for infection. A possible explanation may
be a difference in CMhm viability. While real-time PCR
assays provides reliable quantification of CMhm in blood
samples [87], the true correlation between copy number
and the number of living organisms would require quan-
titative culture, which is not yet possible [80]. A higher
infectivity of the inocula and/or the use of intraperitoneal
(obligatory because of the experimental infection with
FeLV) rather than intravenous administration may explain
the differences compared to previously described courses
of CMhm infection, where the loads peaked in weeks 2 to
4 [81, 82]. Alternatively, the different infection course of
CMhm may have been influenced by the outcome of
FeLV infection itself, but this was not testable in the
experimental setting that was used. Although a relation-
ship between retroviruses (e.g., FeLV or FIV) and coin-
fection with hemotropic mycoplasmas has been postulated
by different authors [23, 27, 42, 81], recent field studies
have found an association for FIV, but not for FeLV
infection [41, 53, 75, 83]. The results presented here
support these findings and show that a retrovirus-positive
status with CMhm coinfection does not necessarily result
in a particular progression or outcome of disease, at least
on a short term. However, it should be noted that these
observations relate to the domestic cat model. Hemotropic
mycoplasma and FeLV may interact specifically in the
Iberian lynx to cause high pathogenicity, but this can only
be tested in an in vitro system, which is unavailable so
far. Thus, the low pathogenicity of the transmitted lynx
FeLV strain in SPF cats underscores the importance of
alterations in host-related factors that, together with
environmental changes, may interact to affect the sus-
ceptibility of Iberian lynxes to disease [13, 64]. For
example, the lack of endogenous FeLV-related sequences
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[56] might also contribute to a higher pathogenicity of
FeLV infection in the Iberian lynxes, since a protective
role of endogenously expressed retroviruses has been
postulated, e.g., for gammaretroviruses in mice [3, 15, 47,
58]. The lack of exposure to pathogens (e.g., FeLV, FIV,
canine distemper virus) might have rendered the Iberian
lynx vulnerable to infections with these pathogens and to
outbreaks of the associated diseases [71]. Nevertheless,
the most important factor may be the loss of genetic
diversity as a consequence of inbreeding (especially in the
Don˜ana region), which resulted in the apparent lack of
acquired immunity and immunocompetence of the Iberian
lynxes against infectious agents [37, 57, 64]. A primary
immune deficiency of the lynxes may have made this
species more vulnerable to infectious diseases — and to
FeLV in particular — a fact that should be thoroughly
investigated and that may pose a real threat to the future
survival of the species.
In conclusion, the results obtained show that the FeLV
strain responsible for the outbreak in Iberian lynxes in
2007 does not harbor potentially highly pathogenic vari-
ants — at least in the genomic regions we have investi-
gated so far. In addition, it has remained stable in its
genetic composition, may undergo partial APOBEC-
mediated restriction and it is apparently not extremely
pathogenic when inoculated into SPF domestic cats.
Hence, we assume that there is no increased risk of
transmission of the lynx FeLV from lynxes to cats and
suggest that the severe outcome of the FeLV outbreak in
2007 was due rather to the particular susceptibility of the
Iberian lynx to pathogens.
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